Public Funding for Meiragtx UK II Limited

"MeiraGTx, Touchlight Genetics and Symbiosis Pharmaceutical Services are collaborating to develop an improved Adeno-associated virus manufacturing process. The process will be improved through a number of different routes to deliver a cost effective large-scale bioreactor manufacturing process for the production of AAV gene therapies Through our collaborative bioreactor development program we will achieve: * An increased yield of infectious AAV particles sufficient to enable the transition of gene therapies from niche to more first line therapy and higher dose indications * A serum free process -- reducing regulatory risk, adventitious agent testing costs, and a source of variability * A synthetic DNA transduction method -- removes common blockages in the manufacturing supply chain, reduces COGs, reducing regulatory risk, reduction in adventitious agent testing costs, and a source of variability * A lower cost of goods due to improved process efficiency, represented by a higher product output from the same GMP suite time"